Physician profile
Michael L Cullen
NPI 1164403598
$6,990.91
in general payments reported to CMS, 2019-2025
42 companies · $764 in 2025
The $764 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $716 · 2020: $340 · 2021: $984 · 2022: $866 · 2023: $1,542 · 2024: $1,780 · 2025: $764.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,081 · Education: $4.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,081.48 |
| Education | $4.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $846.54 | 2021-2025 | |
| Abbvie INC. | $822.98 | 2021-2024 | Ubrelvy, Qulipta, Duopa |
| Biogen, INC. | $565.35 | 2019-2025 | Tysabri, Vumerity |
| Ucb, INC. | $434.79 | 2019-2025 | Rystiggo, Briviact |
| Genentech USA, INC. | $431.72 | 2021-2024 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Lundbeck LLC | $423.15 | 2020-2025 | Vyepti |
| Argenx US, INC. | $381.15 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Sk Life Science, INC. | $378.72 | 2020-2024 | Xcopri |
| Harmony Biosciences LLC | $338.72 | 2023-2024 | Wakix |
| Acadia Pharmaceuticals INC | $335.49 | 2022-2023 | Nuplazid |
| Sunovion Pharmaceuticals INC. | $215.74 | 2019-2021 | |
| Lilly USA, LLC | $207.64 | 2019-2025 | Kisunla, Emgality |
| Teva Pharmaceuticals USA, INC. | $191.23 | 2019-2024 | Austedo Xr |
| Neurocrine Biosciences, INC. | $186.42 | 2022-2023 | Ingrezza |
| Novartis Pharmaceuticals Corporation | $141.62 | 2019-2024 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Cullen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.